Morgan Stanley Reiterates Equal-Weight Rating on Abbott Laboratories

In a report published Monday, Morgan Stanley reiterated its Equal-Weight rating on Abbott Laboratories ABT. Morgan Stanley noted, “The critical debates on the new Abbott are: (i) feasibility of upper-single-digit growth, (ii) magnitude of operating leverage and visibility of double-digit earnings growth and (iii) whether a valuation inefficiency exists. We believe Abbott has set expectations at a fair level and is likely to hit targets for mid- to high-single-digit revenue and 10%+ EPS growth.” Abbott Laboratories closed on Friday at $65.53.